학술논문
De-risking 1st line chemotherapy-free immune checkpoint inhibitor (ICI) use for patients with advanced gastroesophageal cancer (aGEJ) with tumor mutational burden (TMB).
Document Type
Article
Author
Source
Journal of Clinical Oncology; 2024 Supplement 3, Vol. 42, p407-407, 185p
Subject
Language
ISSN
0732183X